Newsroom

Discover the latest news and updates from Almirall.

556 results

CorporatePress release

Almirall continues partnership for second edition of the Hats On For AK initiative

Published on 18 May 2026

The Hats On For AK initiative aims to raise awareness of actinic keratosis and the importance of prevention and early diagnosis of non-melanoma skin cancer.
Almirall is a co founder of the initiative and also proudly supports The Skin Cancer Foundation’s Champions for Change Gala.
As part of its broader commitment to skin health, Almirall is also launching the awareness campaign Skin Scouts: Observe, Detect, Act!, to encourage people to remain vigilant for signs of sun damage and to support early prevention and regular dermatology checkups

Press release

PDF 329.3KB

View Online

InvestorsPress release

Almirall continues its positive trajectory in Q1 2026 in line with expectations – led by 19.3% YoY growth of its European Dermatology business

Published on 11 May 2026

Almirall's European Dermatology business delivered solid growth of 19.3% YoY, reaching €166.3 MM in Q1 2026, driven by strong momentum across key growth drivers. This contributed to overall Net Sales of €291 MM, up 2.2% YoY and reflecting 9% growth on a Last-Twelve-Months (LTM) basis.
Performance continues to be driven by the biologics portfolio, with Ilumetri® showing 11.8% increase in sales vs Q1 2025 (total of €61.6 MM), and Ebglyss® delivering €41.9 MM quarterly sales – more than 2x YoY – boosted by sustained growth in recent launch countries.
Strong performance of the broad dermatology product portfolio in line with expectations - products driving relevance of Almirall in medical dermatology, including Wynzora® (20.8%, total of €9.3 MM) and Klisyri® (7.2%, total of €7.4 MM).
Total EBITDA was €67.5 MM, corresponding to 23.2% over Net Sales - improvement versus FY 2025 (21%).
Continued R&D pipeline progress includes the start of phase I of anti-IL-13/OX40L bispecific antibody, and a new collaboration with China-based biotech Huaota for the development of a novel monoclonal antibody in medical dermatology.
Reiterated guidance for the full year 2026: 9-12% growth and € 270MM to € 290MM EBITDA – scrip dividend of €0.19 per share approved by the AGM on 8th May 2026.

Press release

PDF 209.9KB

View Online

Investors

News

Financial Results Q1 2026

Published on 11 May 2026

Today, we shared our financial results for the first quarter of 2026, continuing our positive trajectory and delivering performance in line with expectations and our long-term growth strategy.

This first quarter marks another step forward in our growth journey, supported by the strong momentum of our European Dermatology business, which grew by 19.3% year-on-year, reaching €166.3 MM. Overall, total Net Sales increased by 2.2% year-on-year to €291 MM, representing a 9% increase on a last twelve months (LTM) basis. These results reflect the consistency of our performance and the strength of the foundations we continue to build.

Our growth continues to be driven by the solid performance of our biologics portfolio and the sustained contribution of our broader dermatology portfolio, reinforcing our position in medical dermatology and supporting long-term value creation.

Profitability also showed a positive evolution, with total EBITDA reaching €67.5 MM, representing 23.2% of Net Sales and an improvement compared to the previous year. This reflects our ongoing focus on operational efficiency and disciplined execution across the business.

During the quarter, we also continued to advance our R&D pipeline, reinforcing our commitment to long-term innovation. Key milestones included the initiation of a new Phase I study and the announcement of a new strategic R&D collaboration, further strengthening our scientific capabilities and future growth potential.

Looking ahead, we remain focused on executing our strategy and sustaining our growth momentum. Our outlook for the full year 2026 remains unchanged, with expected Net Sales growth of 9–12% and EBITDA in the range of €270 MM to €290 MM.

As we continue to deliver on our strategy, we remain committed to transforming today’s science into meaningful solutions for people living with skin conditions.

Investors

News

Annual General Shareholders Meeting

Published on 8 May 2026

Today, we held our Annual General Meeting of Shareholders, reflecting on our continued momentum and steady progress toward our ambition of becoming a global leader in medical dermatology. The meeting provided an update on our performance, strategic priorities, and the key drivers shaping our growth trajectory.

Our strong performance is driven by the solid evolution of our European Dermatology business and the continued expansion of our biologics portfolio. These pillars, together with the advancement of our R&D pipeline, are reinforcing our position and supporting long-term value creation.

A key highlight of the meeting was our transition into a new phase of sustained double-digit growth and margin expansion starting in 2025. This progress reflects our continuous investment in strengthening capabilities across the entire value chain—from research and development to manufacturing and commercial operations—enabling consistent performance and building a strong foundation for future growth.

Looking ahead, we are well positioned to maintain this momentum, supported by a robust pipeline and important R&D milestones expected throughout the year. These advancements will continue to drive innovation and bring new solutions to patients.

The meeting also underscored our commitment to our purpose of transforming the lives of people living with skin conditions. By combining scientific excellence, innovation, and a clear strategic focus, we continue to advance medical dermatology while delivering sustainable growth.

We thank our shareholders for their continued trust and support, which remain key to advancing our long-term vision.

Corporate

News

2025 Year In Review: Entering An Era Of Sustained Growth

Published on 30 April 2026

Today, we launch Almirall’s 2025 Year in Review, a comprehensive publication that looks back on a transformative year and captures the key achievements that shaped our progress throughout 2025. The Year in Review offers a structured and transparent overview of a year defined by accelerated growth, strategic clarity, and a strengthened leadership position in medical dermatology.

Throughout 2025, we continued to advance our growth trajectory in line with our ambition to lead medical dermatology. The Year in Review reflects how this ambition translated into concrete results: the continued expansion of a differentiated dermatology portfolio, steady progress across an exciting R&D pipeline of innovative assets, and strong commercial execution. Together, these elements enabled us to meet our financial guidance while delivering sustained double‑digit sales growth and margin expansion.

Beyond performance, the 2025 Year in Review provides a broader perspective on the drivers behind these results. Readers will find an overview of the year, together with the major milestones that marked the year and a letter from our CEO outlining the strategic context and long‑term direction. The publication also explores how we continue transforming patients’ lives through our portfolio and key products, and how close partnerships with dermatologists remain central to our approach.

In addition, the Year in Review includes a detailed chapter on our financial performance, complemented by insights into our financial outlook and stock performance. It also highlights our focus on innovation as a key enabler of sustainable growth, alongside our continued commitment to sustainability and to the principles of corporate governance that guide responsible decision‑making and long‑term value creation.

By bringing together business results, strategy, innovation, and impact, the 2025 Year in Review captures how 2025 laid solid foundations for the future and reinforces our commitment to advancing medical dermatology through science, innovation, and partnerships.

CorporatePress release

Almirall and Barcelona Supercomputing Center expand their collaboration to accelerate innovation in medical dermatology

Published on 13 April 2026

The strategic framework agreement deepens the long-standing partnership, leveraging Artificial Intelligence and High-Performance Computing to identify new opportunities of collaboration in the discovery of new therapies for skin diseases.
Almirall joins the ‘BSC Connects’ program to foster public-private collaboration and enhance its R&D capabilities.
The alliance strengthens Almirall’s innovation strategy by integrating disruptive technologies to develop advanced dermatological treatments.
The strategic framework agreement deepens the long-standing partnership, leveraging Artificial Intelligence and High-Performance Computing to identify new opportunities of collaboration in the discovery of new therapies for skin diseases.
Almirall joins the ‘BSC Connects’ program to foster public-private collaboration and enhance its R&D capabilities.
The alliance strengthens Almirall’s innovation strategy by integrating disruptive technologies to develop advanced dermatological treatments.

Press release

PDF 91.5KB

View Online

CorporatePress release

Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis

Published on 27 March 2026

In the ADlong Phase 3b study*, 94% of patients achieved meaningful skin improvement (EASI-75) with up to four years of lebrikizumab treatment, reinforcing the sustained response achieved over time in patients with moderate-to-severe atopic dermatitis[i].
75% of patients achieved near-complete skin clearance (EASI-90) and 78% experienced meaningful itch relief (Pruritus NRS ≤4), one of the most bothersome symptoms for patients.
At AAD, Almirall and its partners also presented more than 15 posters across atopic dermatitis, psoriasis, actinic keratosis and acne, strengthening its commitment to improving patient outcomes and aligned with its leadership in medical dermatology.

Press release

PDF 173.0KB

View Online

CorporatePress release

Almirall enters collaboration with Huaota for the development of a novel monoclonal antibody in medical dermatology

Published on 27 March 2026

Huaota will conduct early research and initial clinical development to deliver clinical proof‑of‑concept, while Almirall holds global rights outside China and leads future global development and commercialization.
The agreement further expands Almirall’s innovation strategy in China, building on its growing network of R&D and commercial partnerships in medical dermatology.

Press release

PDF 89.2KB

View Online

CorporatePress release

AAD 2026: Almirall presents new clinical and real‑world evidence across atopic dermatitis, psoriasis, actinic keratosis and acne

Published on 26 March 2026

Almirall advances scientific leadership in medical dermatology with new data across atopic dermatitis, psoriasis, actinic keratosis and acne, reinforcing its commitment to improving patient outcomes.
More than 15 posters will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, including 9 on lebrikizumab, new analyses for tirbanibulin, two on tildrakizumab showing the final 2 year results of the POSITIVE study on patient wellbeing, and new results and analysis for sarecycline.

CorporatePress release

Almirall's 17th Skin Academy highlights scientific advances in inflammatory skin diseases and skin cancer, patient‑reported outcomes, and holistic care in medical dermatology

Published on 23 March 2026

Skin Academy brings together leading global experts to advance innovation, collaboration and scientific understanding in medical dermatology, with a focus on improving quality of life for people living with skin diseases.
This year’s programme featured the latest advancements in the pathophysiology and treatment of atopic dermatitis, including unmet needs in managing the face and neck area. Psoriasis sessions provided insights into the need to individualize treatment across the diverse patient profiles seen in routine clinical practice.
The meeting continues to serve as a leading science-driven platform to exchange best practices and accelerate innovation to address dermatology’s most complex challenges.

Press release

PDF 127.9KB

View Online

12356Next

News type

News

Press releases

Period

Date

Quick Links

Almirall press kit

PDF 2.4MB

View Online

Year in review 2024

PDF 2.7MB

View Online

Almirall at a glance

PDF 22.1MB

View Online

Contact us

Corporate Communications
corporate.communication@almirall.com
+34 932 91 35 08